Chemoprevention of Carcinogen-Induced Lung Cancer
致癌物诱发肺癌的化学预防
基本信息
- 批准号:6872927
- 负责人:
- 金额:$ 42.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-05-01 至 2007-04-30
- 项目状态:已结题
- 来源:
- 关键词:angiogenesis factorbiomarkercancer preventionchemical carcinogenesischemical related neoplasm /cancerchemopreventiondexamethasonedisease /disorder modelenzyme linked immunosorbent assaygenetically modified animalsimmunocytochemistrylaboratory mouselung imaging /visualization /scanninglung neoplasmsmagnetic resonance imagingmicroarray technologymodel design /developmentneoplasm /cancer blood supplyneoplastic growthp53 gene /proteinseleniumsmokingtobacco abuse
项目摘要
DESCRIPTION (provided by applicant)
p53 mutations are found in more than 50% of all human cancers, including lung cancer. These mutations strongly select for p53 proteins that fail to bind to DNA in a sequence-specific fashion. The p53 protein is a tetramer and requires zinc ions for its activity as DNA-binding transcription Lung cancer is the leading cause of cancer death in the United States and the poor lung cancer survival rates argue strongly for new approaches to control this devastating disease. Chemoprevention represents an approach to reverse, suppress, or prevent lung carcinogenesis. Over 80% of lung cancers are attributed to tobacco and carcinogens from cigarette smoke. Even after quitting smoking, former smokers remain at high risk and account for over 50% of current lung cancer cases. With the recent developments in microarray technology, increased insights in lung carcinogenesis will led to the development of targeted intervention and optimism for new chemopreventive approaches to prevent tobacco-related lung cancer, especially in former smokers. We have developed a transgenic mouse model for smoking-related lung cancer by exposure to tobacco carcinogen. The dominant-negative mutant p53 transgene is specifically expressed in the bronchial epithelium under the Clara Cell Specific Protein (CCSP) promoter which results in increased susceptibility to both spontaneous and BaP-induced lung cancer, hence offering a preclinical model for studying chemoprevention of tobacco-related lung cancer. The specific aims are as follows: (1) To establish a mouse model to mimic high risk former smokers and to identify surrogate biomarkers for lung cancer; (2) To determine the efficacy of chemopreventive agents and to validate the use of surrogate biomarkers as endpoints for chemoprevention; (3) To evaluate the use of magnetic resonance imaging (MRI) for assessing tumor growth and and efficacy of chemopreventive agents.
描述(由申请人提供)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KAM-MENG TCHOU-WONG其他文献
KAM-MENG TCHOU-WONG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KAM-MENG TCHOU-WONG', 18)}}的其他基金
Development of cell-permeable antibodies for post-exposure treatment of ricin
开发用于蓖麻毒素暴露后处理的细胞渗透性抗体
- 批准号:
7896982 - 财政年份:2010
- 资助金额:
$ 42.25万 - 项目类别:
Development of cell-permeable antibodies for post-exposure treatment of ricin
开发用于蓖麻毒素暴露后处理的细胞渗透性抗体
- 批准号:
8050650 - 财政年份:2010
- 资助金额:
$ 42.25万 - 项目类别:
New Therapeutic Approach for Ricin-Induced Lung Injury
蓖麻毒素引起的肺损伤的新治疗方法
- 批准号:
7286832 - 财政年份:2006
- 资助金额:
$ 42.25万 - 项目类别:
New Therapeutic Approach for Ricin-Induced Lung Injury
蓖麻毒素引起的肺损伤的新治疗方法
- 批准号:
7150220 - 财政年份:2006
- 资助金额:
$ 42.25万 - 项目类别:
Chemoprevention of Carcinogen-Induced Lung Cancer
致癌物诱发肺癌的化学预防
- 批准号:
6744172 - 财政年份:2003
- 资助金额:
$ 42.25万 - 项目类别:
Chemoprevention of Carcinogen-Induced Lung Cancer
致癌物诱发肺癌的化学预防
- 批准号:
6641360 - 财政年份:2003
- 资助金额:
$ 42.25万 - 项目类别:
Role of H. Pylori Infection in Esophageal Adenocarcinoma
幽门螺杆菌感染在食管腺癌中的作用
- 批准号:
6665481 - 财政年份:2002
- 资助金额:
$ 42.25万 - 项目类别:
相似国自然基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
- 批准号:61602201
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
生物标志物NGAL和KIM-1分子在急性肾损伤中的作用机制研究及标志物联合检测对早期诊断AKI的作用
- 批准号:81101308
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
- 批准号:81170309
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
精神分裂症记忆障碍的脑网络组学研究
- 批准号:91132301
- 批准年份:2011
- 资助金额:350.0 万元
- 项目类别:重大研究计划
卵巢癌血浆microRNA潜在标志物筛选及调控机制研究
- 批准号:81072363
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
高原人群创伤性深静脉血栓血浆预测诊断蛋白标记物的发掘
- 批准号:81060151
- 批准年份:2010
- 资助金额:25.0 万元
- 项目类别:地区科学基金项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
- 批准号:30672394
- 批准年份:2006
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
A novel strategy targeting TP63 for breast cancer prevention
一种针对 TP63 预防乳腺癌的新策略
- 批准号:
10608150 - 财政年份:2022
- 资助金额:
$ 42.25万 - 项目类别:
A novel strategy targeting TP63 for breast cancer prevention
一种针对 TP63 预防乳腺癌的新策略
- 批准号:
10435255 - 财政年份:2022
- 资助金额:
$ 42.25万 - 项目类别:
Gene-tobacco carcinogen interactions and lung cancer risk - a novel approach for precision cancer prevention
基因-烟草致癌物相互作用和肺癌风险——精准癌症预防的新方法
- 批准号:
10581340 - 财政年份:2022
- 资助金额:
$ 42.25万 - 项目类别:
Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America
拉丁美洲资源匮乏地区预防宫颈癌的精准甲基化生物标志物
- 批准号:
10654910 - 财政年份:2021
- 资助金额:
$ 42.25万 - 项目类别:
Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America
拉丁美洲资源匮乏地区预防宫颈癌的精准甲基化生物标志物
- 批准号:
10258144 - 财政年份:2021
- 资助金额:
$ 42.25万 - 项目类别:
Advancing skin cancer prevention by tackling UV-induced clonogenic mutations
通过应对紫外线诱导的克隆突变来促进皮肤癌的预防
- 批准号:
10563186 - 财政年份:2021
- 资助金额:
$ 42.25万 - 项目类别:
Advancing skin cancer prevention by tackling UV-induced clonogenic mutations
通过应对紫外线诱导的克隆突变来促进皮肤癌的预防
- 批准号:
10339333 - 财政年份:2021
- 资助金额:
$ 42.25万 - 项目类别:
Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America
拉丁美洲资源匮乏地区预防宫颈癌的精准甲基化生物标志物
- 批准号:
10666709 - 财政年份:2021
- 资助金额:
$ 42.25万 - 项目类别:
Advancing skin cancer prevention by tackling UV-induced clonogenic mutations
通过应对紫外线诱导的克隆突变来促进皮肤癌的预防
- 批准号:
10097574 - 财政年份:2021
- 资助金额:
$ 42.25万 - 项目类别:
PREVENT PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKER ENDPOINTS TASK ORDER: USE OF CARNOSIC ACID AND VIVOX40 FOR BREAST CANCER PREVENTION
预防临床前功效和中间生物标志物终点任务顺序:使用鼠尾草酸和 VIVOX40 预防乳腺癌
- 批准号:
10453429 - 财政年份:2020
- 资助金额:
$ 42.25万 - 项目类别:














{{item.name}}会员




